ATCC’s Commitment to Tickborne Disease Research
ATCC, a leading global organization in biological materials management, has recently announced its acquisition of a significant subaward intended to propel research on tickborne diseases (TBDs). This one-year subaward, amounting to $165,962, is officially recognized under the project “Parasite-Derived Vesicles in Babesia Virulence and Vaccine Development,” funded by the prominent National Institute of Allergy and Infectious Diseases (NIAID).
Understanding the Impact of Tickborne Diseases
In recent years, the incidence of TBDs has escalated dramatically, with reports from 2004 to 2016 indicating a troubling increase. Strikingly, these cases constituted over 75% of all vector-borne diseases documented across the United States. Among these diseases is human babesiosis, a severe and potentially life-threatening condition caused by Babesia parasites. This ailment is becoming more prevalent on a global scale, highlighting the urgent need for research and preventive measures.
Pioneering Research Efforts
The principal investigator leading this initiative is Dr. Choukri Ben Mamoun, a respected professor at Yale School of Medicine, specializing in Infectious Diseases and Microbial Pathogenesis. He collaborates closely with Dr. Robert Molestina, lead scientist at ATCC. Their joint efforts aim to deepen the scientific understanding of Babesia, including its biology, pathogenesis, and mechanisms of virulence.
The Role of ATCC in Vaccine Development
Dr. Raymond H. Cypess, the chairman and CEO of ATCC, emphasized the significance of elucidating the antigens of the Babesia parasite and the body's immune response to these pathogens. He noted that such insights are essential for the development of viable vaccines against tickborne diseases. Working in partnership with Dr. Ben Mamoun, the focus remains firmly on crafting innovative approaches to vaccine design and delivery.
Advancing Public Health Solutions
ATCC is unwavering in its commitment to tackling infectious diseases, fostering biomarker discovery, and enhancing vaccine initiatives. As stated by Dr. Joseph Leonelli, the senior vice president and general manager of ATCC Federal Solutions, the organization is dedicated to addressing public health challenges posed by TBDs and similar threats. By collaborating extensively with NIAID and innovators like Dr. Ben Mamoun, ATCC is poised to augment its expertise in both in vivo and in vitro research methodologies.
A Vision for the Future
The ongoing research and development initiatives spearheaded by ATCC promise to significantly contribute to the scientific community's understanding and management of tickborne diseases. The advancements from this project are expected to empower researchers and public health professionals to develop effective strategies against the growing threat of these diseases.
About ATCC
ATCC stands as a beacon of advancement in biological materials and information resources. With nearly a century of commitment to scientific excellence, ATCC is recognized as the leading provider of authenticated cell lines, microorganisms, and the critical data necessary for research across various fields including academia, industry, and government. The organization’s extensive collection not only provides reliable resources for scientific research but fosters collaboration among researchers and institutions globally. Headquartered in Virginia and with multiple centers of excellence in Maryland, ATCC remains a nonprofit organization dedicated to supporting public health and scientific endeavors.
Frequently Asked Questions
What is the purpose of the ATCC subaward?
The subaward is intended to enhance research on tickborne diseases, focusing on vaccine development and understanding the underlying biology of pathogens.
Who is leading the research project?
The project is led by Dr. Choukri Ben Mamoun, with Dr. Robert Molestina serving as co-principal investigator.
Why is babesiosis a concern in public health?
Babesiosis is a potentially fatal disease that is emerging worldwide and has significantly increased in the U.S., underlining the need for further research and vaccine development.
How is ATCC contributing to the fight against infectious diseases?
ATCC focuses on infectious disease research, biomarker discovery, and vaccine development to stay ahead of public health threats.
What resources does ATCC provide to the scientific community?
ATCC offers authenticated cell lines, microorganisms, and extensive data, which serve as vital resources for scientific research and innovation.
